Literature DB >> 15533776

Clinical endocrinology and metabolism. Cholecystokinin.

Jens F Rehfeld1.   

Abstract

Cholecystokinin (CCK) is a peptide hormone discovered in the small intestine. Together with secretin and gastrin, CCK constitutes the classical gut hormone triad. In addition to gallbladder contraction, CCK also regulates pancreatic enzyme secretion and growth, intestinal motility, satiety signalling and the inhibition of gastric acid secretion. CCK is, however, also a transmitter in central and intestinal neurons. Notably, CCK is the most abundant neuropeptide in the human brain. Owing to difficulties in developing accurate assays, knowledge about CCK secretion in disease is limited. Available data indicate, however, that proCCK is expressed in certain neuroendocrine tumours and sarcomas, whereas the secretion of CCK is impaired in celiac disease and bulimia nervosa. Stimulation with exogenous CCK has proved useful in diagnostic tests of gallbladder and pancreatic diseases, as well as medullary thyroid carcinomas.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15533776     DOI: 10.1016/j.beem.2004.07.002

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  21 in total

Review 1.  Gastrointestinal hormones regulating appetite.

Authors:  Owais Chaudhri; Caroline Small; Steve Bloom
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

2.  Arx is required for normal enteroendocrine cell development in mice and humans.

Authors:  Aiping Du; Kyle W McCracken; Erik R Walp; Natalie A Terry; Thomas J Klein; Annie Han; James M Wells; Catherine Lee May
Journal:  Dev Biol       Date:  2012-02-24       Impact factor: 3.582

3.  Loss of enteroendocrine cells in mice alters lipid absorption and glucose homeostasis and impairs postnatal survival.

Authors:  Georg Mellitzer; Anthony Beucher; Viviane Lobstein; Pascal Michel; Sylvie Robine; Michèle Kedinger; Gérard Gradwohl
Journal:  J Clin Invest       Date:  2010-04-01       Impact factor: 14.808

Review 4.  Regulating satiety in bulimia nervosa: the role of cholecystokinin.

Authors:  Sandy Hannon-Engel
Journal:  Perspect Psychiatr Care       Date:  2011-04-13       Impact factor: 2.186

5.  Cholecystokinin CCK2 receptors mediate the peptide's inhibitory actions on the contractile activity of human distal colon via the nitric oxide pathway.

Authors:  M Fornai; R Colucci; L Antonioli; F Crema; P Buccianti; M Chiarugi; F Baschiera; N Ghisu; M Tuccori; C Blandizzi; M Del Tacca
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

Review 6.  Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential.

Authors:  Marc J Berna; Jose A Tapia; Veronica Sancho; Robert T Jensen
Journal:  Curr Opin Pharmacol       Date:  2007-11-09       Impact factor: 5.547

7.  Mechanisms of cholecystokinin-induced calcium mobilization in gastric antral interstitial cells of Cajal.

Authors:  Yao-Yao Gong; Xin-Min Si; Lin Lin; Jia Lu
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

8.  CCK-58 elicits both satiety and satiation in rats while CCK-8 elicits only satiation.

Authors:  Joost Overduin; James Gibbs; David E Cummings; Joseph R Reeve
Journal:  Peptides       Date:  2014-01-24       Impact factor: 3.750

9.  Variants in CCK and CCKAR genes to susceptibility to biliary tract cancers and stones: a population-based study in Shanghai, China.

Authors:  Hong-Li Xu; Ann W Hsing; Emily Vogtmann; Lisa W Chu; Jia-Rong Cheng; Jing Gao; Yu-Ting Tan; Bing-Sheng Wang; Ming-Chang Shen; Yu-Tang Gao
Journal:  J Gastroenterol Hepatol       Date:  2013-09       Impact factor: 4.029

Review 10.  Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor.

Authors:  Erin E Cawston; Laurence J Miller
Journal:  Br J Pharmacol       Date:  2009-11-18       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.